Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy

Nanotechnology has played a tremendous role in molecular imaging and cancer therapy. Over the last decade, scientists have worked exceptionally to translate nanomedicine into clinical practice. However, although several nanoparticle-based drugs are now clinically available, there is still a vast dif...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sajid Mushtaq, Asia Bibi, Jung Eun Park, Jongho Jeon
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	technetium-99m nanoparticle molecular imaging cancer therapy radiolabeling Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/a400287c22a849ee9e87c2e47e12b81a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a400287c22a849ee9e87c2e47e12b81a
record_format	dspace
spelling	oai:doaj.org-article:a400287c22a849ee9e87c2e47e12b81a2021-11-25T18:31:47ZRecent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy10.3390/nano111130222079-4991https://doaj.org/article/a400287c22a849ee9e87c2e47e12b81a2021-11-01T00:00:00Zhttps://www.mdpi.com/2079-4991/11/11/3022https://doaj.org/toc/2079-4991Nanotechnology has played a tremendous role in molecular imaging and cancer therapy. Over the last decade, scientists have worked exceptionally to translate nanomedicine into clinical practice. However, although several nanoparticle-based drugs are now clinically available, there is still a vast difference between preclinical products and clinically approved drugs. An efficient translation of preclinical results to clinical settings requires several critical studies, including a detailed, highly sensitive, pharmacokinetics and biodistribution study, and selective and efficient drug delivery to the target organ or tissue. In this context, technetium-99m (<sup>99m</sup>Tc)-based radiolabeling of nanoparticles allows easy, economical, non-invasive, and whole-body <i>in vivo</i> tracking by the sensitive clinical imaging technique single-photon emission computed tomography (SPECT). Hence, a critical analysis of the radiolabeling strategies of potential drug delivery and therapeutic systems used to monitor results and therapeutic outcomes at the preclinical and clinical levels remains indispensable to provide maximum benefit to the patient. This review discusses up-to-date <sup>99m</sup>Tc radiolabeling strategies of a variety of important inorganic and organic nanoparticles and their application to preclinical imaging studies.Sajid MushtaqAsia BibiJung Eun ParkJongho JeonMDPI AGarticletechnetium-99mnanoparticlemolecular imagingcancer therapyradiolabelingChemistryQD1-999ENNanomaterials, Vol 11, Iss 3022, p 3022 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	technetium-99m nanoparticle molecular imaging cancer therapy radiolabeling Chemistry QD1-999
spellingShingle	technetium-99m nanoparticle molecular imaging cancer therapy radiolabeling Chemistry QD1-999 Sajid Mushtaq Asia Bibi Jung Eun Park Jongho Jeon Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy
description	Nanotechnology has played a tremendous role in molecular imaging and cancer therapy. Over the last decade, scientists have worked exceptionally to translate nanomedicine into clinical practice. However, although several nanoparticle-based drugs are now clinically available, there is still a vast difference between preclinical products and clinically approved drugs. An efficient translation of preclinical results to clinical settings requires several critical studies, including a detailed, highly sensitive, pharmacokinetics and biodistribution study, and selective and efficient drug delivery to the target organ or tissue. In this context, technetium-99m (<sup>99m</sup>Tc)-based radiolabeling of nanoparticles allows easy, economical, non-invasive, and whole-body <i>in vivo</i> tracking by the sensitive clinical imaging technique single-photon emission computed tomography (SPECT). Hence, a critical analysis of the radiolabeling strategies of potential drug delivery and therapeutic systems used to monitor results and therapeutic outcomes at the preclinical and clinical levels remains indispensable to provide maximum benefit to the patient. This review discusses up-to-date <sup>99m</sup>Tc radiolabeling strategies of a variety of important inorganic and organic nanoparticles and their application to preclinical imaging studies.
format	article
author	Sajid Mushtaq Asia Bibi Jung Eun Park Jongho Jeon
author_facet	Sajid Mushtaq Asia Bibi Jung Eun Park Jongho Jeon
author_sort	Sajid Mushtaq
title	Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy
title_short	Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy
title_full	Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy
title_fullStr	Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy
title_full_unstemmed	Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy
title_sort	recent progress in technetium-99m-labeled nanoparticles for molecular imaging and cancer therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a400287c22a849ee9e87c2e47e12b81a
work_keys_str_mv	AT sajidmushtaq recentprogressintechnetium99mlabelednanoparticlesformolecularimagingandcancertherapy AT asiabibi recentprogressintechnetium99mlabelednanoparticlesformolecularimagingandcancertherapy AT jungeunpark recentprogressintechnetium99mlabelednanoparticlesformolecularimagingandcancertherapy AT jonghojeon recentprogressintechnetium99mlabelednanoparticlesformolecularimagingandcancertherapy
_version_	1718411036122415104

Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy

Ejemplares similares